Question 1

Should I pick Saxenda or Trulicity?

Accepted Answer

It depends entirely on the indication you are treating. Saxenda (liraglutide 3.0 mg daily) is the only FDA-approved option of the two for chronic weight management, with SCALE Obesity showing −8.0% body-weight reduction at 56 weeks (Pi-Sunyer 2015 NEJM, PMID 26132939). Trulicity (dulaglutide weekly) is approved only for type 2 diabetes — it produces 3-5 kg of weight loss as a side effect but is not labeled for obesity. If you have T2D and want weekly dosing plus documented cardiovascular benefit, Trulicity is the right choice. If your primary problem is obesity without diabetes, Saxenda is the labeled option (though most clinicians now prefer weekly semaglutide or tirzepatide if available).

Question 2

Why is my T2D and obese patient on Trulicity instead of Saxenda?

Accepted Answer

Because Trulicity treats T2D — Saxenda does not. Although liraglutide 1.8 mg (sold as Victoza) is approved for T2D, Saxenda is the 3.0 mg dose strictly labeled for chronic weight management. A patient with both T2D and obesity typically gets Trulicity for diabetes control (weekly dosing, REWIND cardiovascular benefit), and the weight loss comes along as a bonus. Adding Saxenda on top of Trulicity is not standard practice — overlapping two GLP-1 receptor agonists is not recommended. Most clinicians today would consider switching from Trulicity to semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound) for stronger combined T2D + weight benefit.

Question 3

Will my insurance approve either for off-label use?

Accepted Answer

Rarely. Trulicity for weight loss without type 2 diabetes is almost universally denied — payers require A1c ≥6.5% (or ≥6.0% with documented metformin trial) and a T2D ICD-10 code. Saxenda for type 2 diabetes is also denied because Victoza (the lower-dose liraglutide) is the labeled T2D formulation. The PA criteria are brand-specific even when the molecule overlaps. Off-label cash payment runs ~$987/mo for Trulicity at WAC and ~$1,349/mo for Saxenda retail. Manufacturer savings cards (Lilly Trulicity card, NovoCare) require commercial insurance plus an on-label diagnosis.

Question 4

Pediatric — which is approved younger?

Accepted Answer

Trulicity is approved at a younger age. The FDA expanded Trulicity to type 2 diabetes in pediatric patients aged 10 years and older in June 2022 based on the AWARD-PEDS trial. Saxenda is approved for chronic weight management in adolescents aged 12 years and older (BMI corresponding to ≥30 kg/m² for adults, using CDC growth charts). The 2-year gap reflects different indications: Trulicity treats pediatric T2D, Saxenda treats pediatric obesity. Both pediatric approvals require documented BMI/A1c criteria and prescriber supervision; insurance coverage for adolescents is typically more straightforward than off-label adult prescribing.

Question 5

Are daily and weekly really equivalent?

Accepted Answer

No — frequency materially affects adherence and steady-state pharmacology. Saxenda's daily injection schedule has higher real-world discontinuation than weekly GLP-1s, with one-year persistence around 27-35% in claims studies. Trulicity's weekly dosing (4 injections/month vs Saxenda's ~30) drives substantially better adherence — one-year persistence near 50-65%. Steady-state liraglutide concentrations also fluctuate daily (half-life ~13 hours), while dulaglutide's IgG4-Fc-fused structure gives it a ~5-day half-life and flatter steady-state levels. For most patients, weekly dosing is preferred unless a specific clinical reason favors the daily peak (e.g., titration tolerability in adolescents, daily reminder behavior change).

Question 6

Does either have cardiovascular benefit?

Accepted Answer

Trulicity has a direct cardiovascular outcome trial; Saxenda does not. REWIND (Gerstein 2019 Lancet, PMID 31189511) randomized 9,901 T2D patients (only 31% with prior CV disease) to dulaglutide vs placebo for a median 5.4 years and showed MACE HR 0.88 (−12%, p=0.026) — making Trulicity FDA-labeled for cardiovascular risk reduction in T2D regardless of prior CV disease. Saxenda has no dedicated CVOT, but liraglutide 1.8 mg at the T2D dose was studied in LEADER (Marso 2016 NEJM, PMID 27295427), which showed MACE HR 0.87 (−13%). The LEADER data informs the molecule's CV profile but the Saxenda label does not carry a CV risk-reduction indication because the 3.0 mg obesity dose was not the trial dose.

Field	Saxenda	Trulicity
Manufacturer & FDA-approved indication	Novo Nordisk; chronic weight management (BMI ≥30 or ≥27+comorbidity)	Eli Lilly; type 2 diabetes mellitus
Mechanism	GLP-1 receptor agonist (liraglutide; human GLP-1 analog, 97% homology)	GLP-1 receptor agonist (dulaglutide; GLP-1 fused to IgG4 Fc fragment)
Dosing frequency & route	Once-daily subcutaneous injection; titrate 0.6 → 3.0 mg over 5 weeks	Once-weekly subcutaneous injection; 0.75 → 1.5 → 3.0 → 4.5 mg
Weight loss (pivotal trial, max dose)	−8.0 kg / −8.0% at 56 wk (SCALE Obesity, 3.0 mg)	−3.0 to −4.6 kg at 52 wk in T2D (AWARD program, 4.5 mg)
Cardiovascular outcome trial	No Saxenda-specific CVOT; LEADER (liraglutide 1.8 mg T2D dose) MACE −13%	REWIND: MACE HR 0.88 (−12%, p=0.026) in T2D ± prior CV disease
Pediatric approval (FDA label)	Obesity in adolescents ≥12 years (BMI ≥95th percentile)	Type 2 diabetes in pediatric patients ≥10 years
CKD considerations	Renal dose adjustment not required; dehydration / AKI cautions on label	AWARD-7: maintained A1c reduction in moderate-to-severe CKD (eGFR 15-59)
Cash price (manufacturer)	~$1,349/mo retail; no Novo cash-pay program for Saxenda specifically	~$987/mo WAC; Lilly savings card for commercially insured T2D patients

Saxenda vs Trulicity (2026): Liraglutide vs Dulaglutide Verdict

The verdict

Side-by-side comparison

Frequently asked questions